SeaStar Medical Holding Announces The Publication Of A Case Series Of Three Children With Shiga-Toxin-Associated Hemolytic Uremic Syndrome, Who Were Treated With The Selective Cytopheretic Device In The Journal Blood Purification
Portfolio Pulse from Benzinga Newsdesk
SeaStar Medical Holding has announced the publication of a case series involving three children with Shiga-Toxin-Associated Hemolytic Uremic Syndrome, who were treated with the Selective Cytopheretic Device. The case series has been published in the Journal Blood Purification.
August 29, 2023 | 12:16 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
SeaStar Medical Holding's publication of a case series involving the use of the Selective Cytopheretic Device in treating Shiga-Toxin-Associated Hemolytic Uremic Syndrome in children may impact ICU Medical Inc. if the device is adopted in ICUs.
The news pertains to a case series involving the use of SeaStar Medical Holding's Selective Cytopheretic Device in treating Shiga-Toxin-Associated Hemolytic Uremic Syndrome in children. If the device proves effective and is adopted in ICUs, it could potentially impact ICU Medical Inc., a company that provides medical devices for use in critical care settings. However, the direct impact on ICU Medical Inc. is uncertain at this point, hence the neutral score.
CONFIDENCE 70
IMPORTANCE 50
RELEVANCE 50